Archivi tag: Apo A1 Milano

Beyond atheroma regression: clinical outcomes and effect size.

Regression or no progression, of coronary atheroma, in trials with non statin, intensive lipid lowering, injectable treatments.

Great claims but small results, about regression, despite impressive reduction of LDL cholesterol.

Waiting for immininent results of clinical outcomes trials:

Two regression trials, with IVUS imaging, were presented at the AHA 2016 congress, with different results:

  • Milano pilot study, with Apo A1 Mi  (HDL mimetic)
  • Glagov trial, with Evolocumab  (PCSK9 inhibitor)

Continua a leggere